Orange Book product · Generic (ANDA)
DAPSONE
DAPSONE
At a glance
Approved Prior to Jan 1, 1982
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
No patent or exclusivity dates are listed for this product.
Pharmaceutical detail
Active ingredient
DAPSONE
Strength
25MG
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
ANDA 086841
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of DAPSONE
- 2016ACZONEBrand (NDA)
NDA 207154 · ALMIRALL
- 2005ACZONEBrand (NDA)
NDA 021794 · ALMIRALL
- 2026DAPSONEGeneric (ANDA)
ANDA 220103 · ZYDUS LIFESCIENCES
- 2025DAPSONEGeneric (ANDA)
ANDA 218457 · AUROBINDO PHARMA LTD
- 2024DAPSONEGeneric (ANDA)
ANDA 213636 · TP ANDA HOLDINGS
- 2024DAPSONEGeneric (ANDA)
ANDA 214019 · ZYDUS LIFESCIENCES
- 2023DAPSONEGeneric (ANDA)
ANDA 212657 · CHARTWELL RX
- 2023DAPSONEGeneric (ANDA)
ANDA 215087 · CHARTWELL RX
- 2023DAPSONEGeneric (ANDA)
ANDA 215718 · ALEMBIC
- 2023DAPSONEGeneric (ANDA)
ANDA 209890 · AMNEAL
- 2023DAPSONEGeneric (ANDA)
ANDA 212383 · ENCUBE
- 2023DAPSONEGeneric (ANDA)
ANDA 207165 · RISING
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
